ClinicalTrials.gg
RecruitingNCT07673237RESPOND-ILDUpdated Oct 9, 2026

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

An interventional study of Spirometer and Oximeter in Fibrotic Interstitial Lung Disease, IPF and PPF and Lung Fibrosis Interstitial, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Health services research

How we know

Updated Oct 8, 2026Now RecruitingEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Planned enrollment
21st of 90
200 · median 50
Started
2026
with 3 others
No phase
12 of 128
4 open now
Primary completion
2028-08
later than 29 of 38 live
Registered
128th of 128
by date

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 21st largest by planned enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 with no phase, reaches primary completion later than 29 of the 38 other live ones, and was the 128th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.

Read the detailed description

Participants in this 12-month study will use home-based monitoring tools provided by the study and complete electronic patient-reported outcome (ePRO) questionnaires to help assess changes in health status over time. Study procedures include weekly home spirometry for all participants, with some participants also asked to complete daily pulse oximetry monitoring and/or weekly weight measurements, depending on study assignment. The study includes an initial in-person baseline visit and a final in-person visit at Month 12 at the UCSF Interstitial Lung Disease Clinic at the Parnassus Campus. Follow-up study visits at Months 3, 6, and 9 will be conducted remotely via Zoom. Participants will complete study-related assessments throughout the study period using electronic devices and questionnaires from home.

03

Conditions studied

  • Fibrotic Interstitial Lung Disease
  • IPF and PPF
  • Lung Fibrosis Interstitial

Keywords

  • Interstitial lung disease
  • pulmonary fibrosis
  • idiopathic pulmonary fibrosis
  • progressive pulmonary fibrosis
  • Remote patient monitoring
  • Digital health
  • Telemonitoring
  • Home monitoring
  • Pragmatic study design
  • Real-world monitoring
  • Decentralized clinical trial
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 or older
  • English speaking
  • have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for >10% of the ILD diagnoses seen at UCSF.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable provide for any reason or are acutely ill.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Spirometry Only

    Participants randomized to Arm 1 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece). Participants will also complete brief symptom questionnaires electronically throughout the study period.

    Device: Spirometer · Other: ePROs (electronic patient reported outcomes)

  • Experimental
    Spirometer and Oximeter

    Participants randomized to Arm 2 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece) and will measure oxygen saturation levels daily using a pulse oximeter. Participants will also complete brief electronic symptom questionnaires throughout the study period.

    Device: Spirometer · Device: Oximeter · Other: ePROs (electronic patient reported outcomes)

  • Experimental
    Spirometer and Scale (weight)

    Participants randomized to Arm 3 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece) and will measure their weight weekly using the wireless scale provided by the study. Participants will also complete brief electronic symptom questionnaires throughout the study period.

    Device: Spirometer · Device: Scale · Other: ePROs (electronic patient reported outcomes)

  • Experimental
    Spirometer, Oximeter, and Scale (weight)

    Participants randomized to Arm 4 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece), measure oxygen saturation levels daily using a pulse oximeter, and measure their weight weekly using the wireless scale provided by the study. Participants will also complete brief electronic symptom questionnaires throughout the study period.

    Device: Spirometer · Device: Oximeter · Device: Scale · Other: ePROs (electronic patient reported outcomes)

Interventions

  • DeviceSpirometer

    Home spirometry will be conducted weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece).

  • DeviceOximeter

    Oxygen saturation levels will be measured daily using a pulse oximeter.

  • DeviceScale

    Weight will be measured weekly using a wireless scale provided by the study.

  • OtherePROs (electronic patient reported outcomes)

    Brief electronic symptom questionnaires will be completed through a secure app which will be downloaded on participant's phone.

06

What researchers measure

Primary outcomes

  1. Detection rate of clinically significant ILD events

    Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months

    Time frame: Baseline, Month 12

  2. Time to detection of first ILD event

    Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months.

    Time frame: Baseline, Month 12

  3. Adherence

    Adherence to remote monitoring protocol, defined as the proportion of measurements completed \>=67% of weeks with full data entry)

    Time frame: 12 months

  4. Retention

    Primary: Participant retention at 12 months (target \>=80%)

    Time frame: 12 months

  5. Data Completeness

    Data completeness, defined as \>85% of expected remote monitoring data points successfully transmitted

    Time frame: 12 months

Secondary outcomes

  1. Change in health-related quality of life

    Measured by administration of King's Brief ILD Questionnaire (K-BILD). K-BILD is a 15-item health status questionnaire with each item reported on a 7-point Likert response scale across three domains: breathlessness and activities, psychological, chest symptoms. The raw scores are logit transformed onto a standardized 0-100 scale, where 100 represents the best health status. The minimally clinically important change difference for the total score is = 5-point change.

    Time frame: Baseline, Month 12

  2. Change in health-related quality of life

    Measured by administration of the Generalized Anxiety Disorder 7-item scale (GAD-7). The GAD-7 scores each of the 7 items on a scale of 0-3 with the total score range from 0-21 with a higher score indicating higher anxiety.

    Time frame: Baseline, Month 12

  3. Change in FVC

    Measured by comparing changes in FVC in home spirometry vs clinic-based spirometry

    Time frame: Baseline, Month 12

  4. Proportion of patients with ≥10% decline in FVC

    Measured by FVC values collected through home spirometry.

    Time frame: Baseline, Month 12

  5. Proportion of patients with a change in ILD-related treatment

    Measured by collecting data on initiation, discontinuation, or dose adjustment of antifibrotic medication, immunosuppressive therapy, oxygen therapy, referral for transplant evaluation, or referral to pulmonary rehabilitation.

    Time frame: Baseline, Month 12

  6. Patient Engagement and Activation

    Patient engagement and activation, as measured by the Patient Activation Measure (PAM) which assess a patient's knowledge, skill, and confidence for self-managing their health. The 13 items are measured on a 4-point Likert scale, with the raw total transformed into a standardized score of 0-100 where higher scores indicate greater activation.

    Time frame: 12 months

  7. Patient-reported Satisfaction

    Patient-reported satisfaction, acceptability and burden of monitoring as measured by survey adapted from Home Monitoring Acceptance and Satisfaction Questionnaire (HoMASQ). The ten item questionnaire scores each item on a 1-5 Likert scale with the total score ranging from 10 to 50. A higher score means higher patient satisfaction.

    Time frame: 12 months

  8. Total implementation cost of home monitoring intervention components (per-patient, US dollars)

    Total cost of delivering the home monitoring intervention, calculated as the sum of intervention costs (per-unit cost of the home spirometer, pulse oximeter, and/or weight scale, plus electronic patient-reported outcome \[ePRO\] platform licensing and data transmission fees) and implementation costs (personnel time for device provisioning, patient training, technical support, and clinician review of transmitted data, valued using time-driven activity-based costing and applicable wage rates). Cost will be calculated per patient over the 12-month active monitoring period, in US dollars. Consistent with the factorial MOST design, total cost will be analyzed by main effect - oximeter (Arms 2 and 4 combined vs. Arms 1 and 3 combined) and weight scale (Arms 3 and 4 combined vs. Arms 1 and 2 combined).

    Time frame: 12 month

  9. Unintended Implementation Impact

    Number of unscheduled clinical contacts or escalations triggered by remote monitoring

    Time frame: 12 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ilowite J, Lisker G, Greenberg H. Digital Health Technology and Telemedicine-Based Hospital and Home Programs in Pulmonary Medicine During the COVID-19 Pandemic. Am J Ther. 2021 Feb 3;28(2):e217-e223. doi: 10.1097/MJT.0000000000001342. PubMed 33590991 ↗
  • Handley MA, Lyles CR, McCulloch C, Cattamanchi A. Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annu Rev Public Health. 2018 Apr 1;39:5-25. doi: 10.1146/annurev-publhealth-040617-014128. Epub 2018 Jan 12. PubMed 29328873 ↗
  • Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 Oct 15;194(8):989-997. doi: 10.1164/rccm.201511-2152OC. PubMed 27089018 ↗
  • Ku JP, Sim I. Mobile Health: making the leap to research and clinics. NPJ Digit Med. 2021 May 14;4(1):83. doi: 10.1038/s41746-021-00454-z. PubMed 33990671 ↗
  • Ge J, Fontil V, Ackerman S, Pletcher MJ, Lai JC. Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis. Hepatology. 2025 Apr 1;81(4):1353-1364. doi: 10.1097/HEP.0000000000000583. Epub 2023 Aug 23. PubMed 37611253 ↗
  • Farrand E, Gologorskaya O, Mills H, Radhakrishnan L, Collard HR, Butte AJ. Machine-Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease. Am J Respir Crit Care Med. 2023 May 15;207(10):1398-1401. doi: 10.1164/rccm.202211-2092LE. No abstract available. PubMed 36943196 ↗
  • Sim I. Mobile Devices and Health. N Engl J Med. 2019 Sep 5;381(10):956-968. doi: 10.1056/NEJMra1806949. No abstract available. PubMed 31483966 ↗
  • Odisho AY, Liu AW, Maiorano AR, Bigazzi MOA, Medina E, Leard LE, Shah R, Venado A, Perez A, Golden J, Kleinhenz ME, Kolaitis NA, Maheshwari J, Trinh BN, Kukreja J, Greenland J, Calabrese D, Neinstein AB, Singer JP, Hays SR. Design and implementation of a digital health home spirometry intervention for remote monitoring of lung transplant function. J Heart Lung Transplant. 2023 Jun;42(6):828-837. doi: 10.1016/j.healun.2023.01.010. Epub 2023 Feb 2. PubMed 37031033 ↗
  • Wijsenbeek MS, Moor CC, Johannson KA, Jackson PD, Khor YH, Kondoh Y, Rajan SK, Tabaj GC, Varela BE, van der Wal P, van Zyl-Smit RN, Kreuter M, Maher TM. Home monitoring in interstitial lung diseases. Lancet Respir Med. 2023 Jan;11(1):97-110. doi: 10.1016/S2213-2600(22)00228-4. Epub 2022 Oct 4. PubMed 36206780 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2028, 22 months later.

Of 41 interventional studies with no phase under Pulmonary Fibrosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 81. This study's planned 22 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 29, 2026
StartEst.
Oct 1, 2026was Aug 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
University of California, San Francisco is now Recruiting
Oct 5, 2026
Start date
Aug 1, 2026→Oct 1, 2026
Oct 5, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEnglish or Spanish speaking
Oct 8, 2026
Interventions
Added Device: Spirometer·Device: Oximeter·Device: Scale·ePROs (electronic patient reported outcomes); removed Behavioral: Home Monitoring in Patients with f-ILD
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of California, San Francisco · San Francisco, United StatesContact added Y•••@ucsf.edu · •••9744Contact added (no phone or email listed)
Oct 5, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEnglish or Spanish speaking
    + 1 other change: verification date
  2. Oct 5, 2026
    Not yet recruiting→Recruiting
    University of California, San Francisco is now Recruiting
    Start date Aug 1, 2026→Oct 1, 2026
    Interventions Added Device: Spirometer·Device: Oximeter·Device: Scale·ePROs (electronic patient reported outcomes); removed Behavioral: Home Monitoring in Patients with f-ILD
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of California, San Francisco · San Francisco, United StatesContact added Y•••@ucsf.edu · •••9744Contact added (no phone or email listed)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07673237
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), patientMpower Ltd.
Responsible party
Erica Farrand, MD (PI, University of California, San Francisco) — Principal investigator
First posted
Jun 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Erica D Farrand, MD
Contact
Erica.Farrand@ucsf.edu
415-476-8067
Yeji Lee
Contact
Yeji.Lee@ucsf.edu
415-353-9744
Erica Farrand, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion